Background-This trial was carried out to assess the value of propranolol in the prevention of recurrent variceal bleeding when combined with longterm endoscopic sclerotherapy. Patients and methods-Two hundred patients (161 male, 39 female, age range 20-68 years) with portal hypertension resulting mainly from schistosomal periportal fibrosis or posthepatitic cirrhosis presenting with their first episode of haematemesis or melena, or both were included. This was confirmed endoscopically to result from ruptured oesophageal varices. After initial control of bleeding, patients were randomised into two groups: group 1 treated with endoscopic sclerotherapy alone and group 2 treated with sclerotherapy plus propranolol. They were followed up for two years. Results-Group (2) had a lower rebleeding rate (14.3% v 38.6% in group 1), lower variceal recurrence after obliteration (1/7% v 34% in group 1), longer period between variceal obliteration and recurrence (36 weeks v 21 weeks in group 1); but no change in mortality (12% in both groups). Conclusions-Patients treated with sclerotherapy should be given propranolol for longterm management.
Bleeding from oesophageal varices is an important cause of morbidity and mortality in cirrhotic patients,l as well as in patients with hepatosplenic schistosomiasis.2 Once a patient has bled from varices the risk of rebleeding is 70% or more.3 Endoscopic sclerotherapy is widely used for treatment of bleeding from ruptured oesophageal varices.4 Randomised controlled studies have shown that patients treated with sclerotherapy rebleed significantly less often than control patients treated conservatively.5-7 However, before variceal obliteration, sclerotherapy treated patients may experience a rebleeding rate as high as 50%. 8 Propranolol has been shown to decrease portal pressure and to be more effective in preventing variceal rebleeding than placebo,9 10 although some studies have given conflicting results." 12 Studies comparing a combination of sclerotherapy and propranolol versus sclerotherapy alone have given discordant results. [13] [14] [15] The aim of this study was to compare endoscopic sclerotherapy alone with endoscopic sclerotherapy plus propranolol in patients with portal hypertension and variceal bleeding.
Methods Inclusion criteria:
(1) First episode of upper gastrointestinal haemorrhage endoscopically confirmed to originate from oesophageal varices. Patients with gastric varices or ulcers were excluded from the study.
(2) No history of treatment with propranolol, or shunt surgery. (4) No other serious disease that could affect the outcome of the study, for example, associated malignancy or renal failure.
Oesophageal varices were graded according to a previously published classification. '5 Two hundred patients fulfilling the inclusion criteria presented at Al-Mansoura, Internal Medicine Department and were considered for the study from April 1991 until October 1991. After initial resuscitation, the bleeding episode was treated with balloon tamponade, vasopressin (Glypressin) and blood transfusion as required. All patients were then treated with endoscopic sclerotherapy. Twenty two patients were excluded from the study within the first day after admission (15 died and seven had a deteriorating course passing a hepatic precoma stage).
After resuscitation 178 patients were randomised into two groups using sealed opaque envelopes; group 1 was treated with endoscopic sclerotherapy alone (87 patients) and group 2 was treated with endoscopic sclerotherapy and propranolol (91) patients. All gave their informed consent to participate in the study. The patients were followed up for 17 to 24 months with a mean of 21 months. The study ended April 1993, 140 patients completed the study (70 in each group). Thirty three patients failed to comply to the sessions of sclerotherapy or oral propranolol therapy or did not attend the follow up despite reminders sent to their last known addresses. Five patients decided to have a shunt surgery.
Sclerotherapy
The free-hand technique was used with ethanolamine oleate 5% as the sclerosant. An intravariceal injection was given every two Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleedingfrom oesophageal varices: a randomised study 10Group I IGroupIl after bleeding. A lesion was considered to be the cause of bleeding if presented with a clot on its surface, or it was seen actively bleeding, or no other lesion in the upper gastrointestinal tract could possibly have bled.
After the bleeding has been controlled, patients continued with the same treatment as previously.
o ' 20-30 [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Age (y) Pneumonia was recorded as the cause of death in two cases (one in each group) in whom emergency sclerotherapy was done.
Thirteen patients (9% of all patients) developed mild pleural effusion on x ray and resolved completely.
Other minor side effects in the form of mild fever for one to two days, retrosternal discomfort or pain, and supefficial oesophageal ulcerations at the injection sites were recorded and treated without affecting the final outcome. there was a highly significant (p<0001) low rebleeding rate in group 2 (14.3%) v group (38.6%).
The number of rebleeding episodes in rel tion to time of follow up was recorded and t] peak incidence was seen in the first 10 weeks both groups (NS) (Figs 4 and 5) .
The mean total blood requirement p patient was significantly lower in group 2 (1 (3.7) v 2.9 (6.7) units of blood in group p<001).
Mortality
The death rate was found to be 12% for patients, with non-significant differen between both groups (Fig 6) France (71%) after 14 weeks' follow up who also reported a non-significant difference between patients treated with sclerotherapy alone and those treated with sclerotherapy plus propranolol. 15 The time needed to achieve obliteration of the varices was similar in both groups in this study with a mean of 9-5 weeks, which corresponds to a mean of four sessions of sclerotherapy in each group. These results are in accordance with those recorded by other investigators who showed that propranolol had no effect on obliteration rate and time when added to sclerotherapy.13 15 20 The main disadvantage of sclerotherapy is the eventual recurrence of varices in many patients. Terblanche In this study the rebleeding rate in all patients was found to be 26@4% with a significantly lower rate (13@3%) in group 2 when compared with group 1 (38-6%) (p<0 001).
These results are in agreement with other inlvestigators.14 15 25 On the other hand Vickers26 reported a non-significant difference between patients treated with sclerotherapy plus propranolol and those treated with sclerotherapy alone in terms of rebleeding after two years of follow up of 69 patients with cirrhosis. Also others13 20 have reported that propranolol did not significantly reduce the frequency of rebleeding until variceal obliteration by sclerotherapy, these two studies comparing 41 and 53 cirrhotic patients respectively.
This difference in rebleeding rate between this study and those three studies could be explained by the fact that these studies included comparatively small number of patients with advanced liver cirrhosis and the causes of rebleeding in most cases were attributed to mucosal ulcerations and to congestive gastropathy whereas in our study variceal bleeding was considered the main cause of rebleeding. Actual bleeding from non-variceal sites was extremely uncommon in our patients, which is similar to the findings of other studies by Vinel15 and Westaby.27 In this study rebleeding was significantly higher in patients with grade C Pugh-Child's classification, when compared with grade B or grade A patients of the same group. This is in agreement with Garrett, 8 and Balanzo.28 Although the combination of propranolol and sclerotherapy was found to be superior to sclerotherapy alone in prevention of rebleeding, it does not affect the death rate. Seventeen patients died (12% of patients included) with a non-significant difference between both groups. These results are in agreement with many studies. 14 15 25 27 The mean initial daily dose of propranolol in this study was 90 mg and the mean maintenance does was 30 mg/day. This resulted in reduction of resting heart rate by about 25%. These doses are generally smaller than those of other studies where the mean daily dose was 105 mg,15 54 mg,29 120 mg,13 27 71 mg,30 and 160 mg.25
This could be explained by the fact that propranolol has a wide variation in its bioavailability, which varies according to the severity and aetiology of liver disease31 and by changes in its absorption.32
Propranolol in this study was well tolerated and the side effects were minimal. Moreover there was no significant difference in hepatic encephalopathy when comparing both groups despite previous reports that implicated propranolol in the precipitation of encephalopathy.27 33 Also other studies reported a higher incidence of hepatic encephalopathy in a placebo group than in patients treated with propranolol.3435
In conclusion this study provides support for the longterm use of propranolol plus endoscopic sclerotherapy for the prevention of rebleeding from oesophageal varices although the overall death rate is not affected. 
